FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 319:1563-1567 December 15, 1988 Number 24 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

The administration of androgens to adolescent boys with constitutional delay in growth has been highly controversial because of the possibility of premature epiphyseal closure and reduced final height. We have treated 15 such boys with a mean (+/- SD) age of 14.1 +/- 1.0 years and a mean initial height of 142.2 +/- 8.6 cm (range, 127.1 to 156.2). The boys received monthly intramuscular injections of testosterone enanthate (50 mg) for 1.2 +/- 0.3 years. The mean height velocity rose from the 3rd percentile for mean skeletal age to above the 90th percentile, where it remained throughout treatment. Although skeletal maturation accelerated initially in the seven boys with a skeletal age under the pretreatment group mean of 11.3 years, it advanced normally in the others. The concomitant increase in stature was sufficient to offset the advancement in skeletal age in most boys, so that the mean predicted adult height was essentially unaffected. Sexual maturation also progressed; testicular volume increased from 5.9 +/- 2.7 to 11.3 +/- 2.7 ml. After treatment, the skeletal age advanced normally and sexual development continued. Eight of the boys are now 18.1 +/- 0.5 years of age and have stopped growing; their present mean height (167.6 +/- 4.7 cm) is very close to their pretreatment predicted height of 168.0 +/- 5.6 cm. We conclude that low-dose testosterone treatment is effective in adolescent boys with delayed growth and development and that it does not appear to compromise final adult height.

Source Information

Department of Pediatrics, State University of New York Health Science Center, Syracuse.

This article has been cited by other articles:

• Collett-Solberg, P. F., Misra, M., on behalf of the Drug and Therapeutics Committee o, (2008). The Role of Recombinant Human Insulin-Like Growth Factor-I in Treating Children with Short Stature. J. Clin. Endocrinol. Metab. 93: 10-18 [Abstract] [Full Text]  
• Stein, M. T., Frasier, S. D., Stabler, B. (2004). Parent Requests Growth Hormone for Child With Idiopathic Short Stature. Pediatrics 114: 1478-1482 [Full Text]  
• Vidal, O., Lindberg, M. K., Hollberg, K., Baylink, D. J., Andersson, G., Lubahn, D. B., Mohan, S., Gustafsson, J.-A., Ohlsson, C. (2000). Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice. Proc. Natl. Acad. Sci. USA 97: 5474-5479 [Abstract] [Full Text]  
• Winters, S. J. (1999). Current Status of Testosterone Replacement Therapy in Men. Arch Fam Med 8: 257-263 [Abstract] [Full Text]  
• Arslanian, S., Suprasongsin, C. (1997). Testosterone Treatment in Adolescents with Delayed Puberty: Changes in Body Composition, Protein, Fat, and Glucose Metabolism. J. Clin. Endocrinol. Metab. 82: 3213-3220 [Abstract] [Full Text]  
• Zacharin, M R, Warne, G L (1997). Treatment of hypogonadal adolescent boys with long acting subcutaneous testosterone pellets. Arch. Dis. Child. 76: 495-499 [Abstract] [Full Text]  
• (1988). TESTOSTERONE TREATMENT FOR SHORT STATURE IN BOYS. JWatch General 1988: 7-7 [Full Text]